Top
Summary
All studies
Exclusions
Mortality
Ventilation
Hospitalization
Serious outcomes
Recovery
Viral clearance
RCTs
Peer-reviewed
All outcomes

Feedback
 
Analgesics⏵
Antiandrogens⏵
Antihistamines⏵
Budesonide
Colchicine
Conv. Plasma
Curcumin
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle⏵
Melatonin
Metformin
Minerals⏵
Monoclonals⏵
Mpro inhibitors⏵
Naso/orophar..⏵
Nigella Sativa
Nitazoxanide
PPIs
Quercetin
RdRp inhibitors⏵
TMPRSS2 inh.⏵
Thermotherapy
Vitamins⏵
More⏵

Other
Feedback
Home
 
Top
..
All mebendazole studies
..
Feedback
Home
c19early.org COVID-19 treatment researchMebendazoleMebendazole (more..)
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta
Ivermectin Meta
Thermotherapy Meta
Melatonin Meta
Metformin Meta
Home Adoption Other Treatments
@CovidAnalysis

Outcomes in COVID-19 mebendazole studies

Home
@CovidAnalysis
All
Studies
Feedback
All studies   Exclusions   Mortality   Ventilation   Hospitalization   Serious outcomes   Recovery   Viral clearance   RCTs   Peer-reviewed   All outcomes  
0 0.5 1 1.5+ All studies 62% 3 411 Improvement, Studies, Patients Relative Risk Mortality 51% 1 157 Ventilation 63% 1 157 Hospitalization 31% 2 342 Viral clearance 85% 1 69 RCTs 85% 1 69 Early 68% 2 254 Late 51% 1 157 Mebendazole for COVID-19 c19early.org May 2025 after exclusions Favorsmebendazole Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Galal 52% 0.48 [0.12-1.88] hosp. 3/94 6/91 Improvement, RR [CI] Treatment Control El-Tanani (DB RCT) 85% 0.15 [0.02-0.94] viral load 34 (n) 35 (n) Tau​2​ = 0.01, I​2​ = 2.1%, p = 0.042 Early treatment 68% 0.32 [0.11-0.96] 3/128 6/126 68% lower risk Galal 51% 0.49 [0.14-1.78] death 3/68 8/89 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.28 Late treatment 51% 0.49 [0.14-1.78] 3/68 8/89 51% lower risk All studies 62% 0.38 [0.17-0.88] 6/196 14/215 62% lower risk 3 mebendazole COVID-19 studies c19early.org May 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.023 Effect extraction pre-specified(most serious outcome) Favors mebendazole Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ El-Tanani (DB RCT) 85% 0.15 [0.02-0.94] viral load 34 (n) 35 (n) Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.042 Early treatment 85% 0.15 [0.02-0.94] 34 (n) 35 (n) 85% lower risk Galal 51% 0.49 [0.14-1.78] death 3/68 8/89 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.28 Late treatment 51% 0.49 [0.14-1.78] 3/68 8/89 51% lower risk All studies 67% 0.33 [0.11-0.99] 3/102 8/124 67% lower risk 2 mebendazole COVID-19 studies after exclusions c19early.org May 2025 Tau​2​ = 0.05, I​2​ = 7.6%, p = 0.047 Effect extraction pre-specified(most serious outcome) Favors mebendazole Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Galal 51% 0.49 [0.14-1.78] 3/68 8/89 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.28 Late treatment 51% 0.49 [0.14-1.78] 3/68 8/89 51% lower risk All studies 51% 0.49 [0.14-1.78] 3/68 8/89 51% lower risk 1 mebendazole COVID-19 mortality result c19early.org May 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.28 Favors mebendazole Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Galal 63% 0.37 [0.08-1.74] 2/68 7/89 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.21 Late treatment 63% 0.37 [0.08-1.74] 2/68 7/89 63% lower risk All studies 63% 0.37 [0.08-1.74] 2/68 7/89 63% lower risk 1 mebendazole COVID-19 mechanical ventilation result c19early.org May 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.21 Favors mebendazole Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Galal 52% 0.48 [0.12-1.88] hosp. 3/94 6/91 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.3 Early treatment 52% 0.48 [0.12-1.88] 3/94 6/91 52% lower risk Galal 30% 0.70 [0.57-0.87] hosp. time 68 (n) 89 (n) Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.001 Late treatment 30% 0.70 [0.57-0.87] 68 (n) 89 (n) 30% lower risk All studies 31% 0.69 [0.56-0.86] 3/162 6/180 31% lower risk 2 mebendazole COVID-19 hospitalization results c19early.org May 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.00065 Favors mebendazole Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Galal 52% 0.48 [0.12-1.88] hosp. 3/94 6/91 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.3 Early treatment 52% 0.48 [0.12-1.88] 3/94 6/91 52% lower risk Galal 51% 0.49 [0.14-1.78] death 3/68 8/89 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.28 Late treatment 51% 0.49 [0.14-1.78] 3/68 8/89 51% lower risk All studies 51% 0.49 [0.19-1.24] 6/162 14/180 51% lower risk 2 mebendazole COVID-19 serious outcomes c19early.org May 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.13 Effect extraction pre-specified(most serious outcome) Favors mebendazole Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Galal 43% 0.57 [0.41-0.80] recov. time 94 (n) 91 (n) Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.001 Early treatment 43% 0.57 [0.41-0.80] 94 (n) 91 (n) 43% lower risk All studies 43% 0.57 [0.41-0.80] 94 (n) 91 (n) 43% lower risk 1 mebendazole COVID-19 recovery result c19early.org May 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.001 Favors mebendazole Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ El-Tanani (DB RCT) 85% 0.15 [0.02-0.94] viral load 34 (n) 35 (n) Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.042 Early treatment 85% 0.15 [0.02-0.94] 34 (n) 35 (n) 85% lower risk All studies 85% 0.15 [0.02-0.94] 34 (n) 35 (n) 85% lower risk 1 mebendazole COVID-19 viral clearance result c19early.org May 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.042 Favors mebendazole Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ El-Tanani (DB RCT) 85% 0.15 [0.02-0.94] viral load 34 (n) 35 (n) Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.042 Early treatment 85% 0.15 [0.02-0.94] 34 (n) 35 (n) 85% lower risk All studies 85% 0.15 [0.02-0.94] 34 (n) 35 (n) 85% lower risk 1 mebendazole COVID-19 Randomized Controlled Trial c19early.org May 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.042 Effect extraction pre-specified(most serious outcome) Favors mebendazole Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Galal 52% 0.48 [0.12-1.88] hosp. 3/94 6/91 Improvement, RR [CI] Treatment Control El-Tanani (DB RCT) 85% 0.15 [0.02-0.94] viral load 34 (n) 35 (n) Tau​2​ = 0.01, I​2​ = 2.1%, p = 0.042 Early treatment 68% 0.32 [0.11-0.96] 3/128 6/126 68% lower risk Galal 51% 0.49 [0.14-1.78] death 3/68 8/89 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.28 Late treatment 51% 0.49 [0.14-1.78] 3/68 8/89 51% lower risk All studies 62% 0.38 [0.17-0.88] 6/196 14/215 62% lower risk 3 mebendazole COVID-19 peer reviewed studies c19early.org May 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.023 Effect extraction pre-specified(most serious outcome) Favors mebendazole Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Galal 52% 0.48 [0.12-1.88] hosp. 3/94 6/91 Improvement, RR [CI] Treatment Control Galal 43% 0.57 [0.41-0.80] recov. time 94 (n) 91 (n) El-Tanani (DB RCT) 85% 0.15 [0.02-0.94] viral load 34 (n) 35 (n) El-Tanani (DB RCT) 59% 0.41 [0.09-1.98] viral+ 2/34 5/35 Galal 51% 0.49 [0.14-1.78] death 3/68 8/89 Galal 63% 0.37 [0.08-1.74] ventilation 2/68 7/89 Galal 30% 0.70 [0.57-0.87] hosp. time 68 (n) 89 (n) Mebendazole COVID-19 outcomes c19early.org May 2025 Favors mebendazole Favors control
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. IMA and WCH provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit    
Post
Share
@CovidAnalysis
FAQ
Public domain CC0 1.0